Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics:

• in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification).
• newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).

The study aims to evaluate patients with hodgkin lymphoma in complete remission for at least 2 years and newly diagnosed (stage II b, stage III or stage IV) as they are currently characterised by a long life expectancy during which there is an increased and early incidence of non-neoplastic systemic complications as well as, of course, manifestations of secondary malignancies.

Inclusion Criteria:

• hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma
• Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy
• Patients of both sexes aged ≥ 18 years at enrollment
• Signature of informed consent

Exclusion Criteria:

• Concomitant second neoplasm